The Federal Trade Commission (FTC) recently cleared Amgen’s (AMGN) $28.7 billion buyout of Horizon Therapeutics after initially raising drug-bundling concerns. This clears the path for Amgen to close on its acquisition, one of the latest in a string of mergers and acquisitions in the pharmaceutical and “MedTech” space. That warrants exploring the future of SS Innovations International (SSII) and whether it could wind up in someone’s crosshairs, writes John McCamant, special to MoneyShow.

Esperion (ESPR) continues to showcase their positive CLEAR data with two oral presentations at the European Society of Cardiology (ESC) 2023 Congress, notes John McCamant, editor of The Medical Technology Stock Letter.

Alkermes (ALKS) recently reported their financials and reiterated fiscal year 2023 guidance which was updated in mid-June, when the company announced the final award from arbitration with Johnson & Johnson (JNJ), recalls John McCamant, biotech expert and editor of The Medical Technology Stock Letter.

Industry analysts estimate that robots account for 2% of surgical procedures worldwide. In the general surgery realm, approximately 10% of procedures in the US leverage robotics, compared to less than 1% outside the country. In other words, there is certainly significant room for further growth in the market, writes John McCamant, special to MoneyShow.

With hundreds of biotech companies to invest in, stock selection is paramount. In this session John will highlight past biotech winners to help frame current biotech recommendations.